Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07155694 · ClinicalTrials.gov registry record · Phase 4
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
A Phase 4 study, sponsored by Washington D.C. Veterans Affairs Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07155694 is a Phase 4 study that has not yet begun recruiting, run by Washington D.C. Veterans Affairs Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT07155694, a Phase 4 study, has not yet begun recruiting, sponsored by Washington D.C. Veterans Affairs Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone or combination therapy. Secondary Objectives: (1). Correlate changes in exosome-based PSP with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. (2) with systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12), hs-CRP and (3) arterial stiffness measures and with (4) APOL1 mRNA expression levels in peripheral blood derived mononuclear cells (MNC).
Interventions
- DRUG Empagliflozin 10 MG
- DRUG Finerenone 10 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07155694
The ClinicalTrials.gov registry entry for NCT07155694 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington D.C. Veterans Affairs Medical Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Empagliflozin 10 MG is the first listed.
NCT07155694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07155694 about?
NCT07155694 is a clinical study titled "Role of Finerenone in African American Veterans With Diabetic Kidney Disease". Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone...
What is the current status of trial NCT07155694?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-09. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07155694?
The interventions under investigation include: Empagliflozin 10 MG (DRUG), Finerenone 10 MG (DRUG).
Who is sponsoring clinical trial NCT07155694?
This trial is sponsored by Washington D.C. Veterans Affairs Medical Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.